Science-led.
Mission-driven.
Globally connected.
EdiLabs is built by a multidisciplinary team with deep expertise across neuroscience, vaccine development, plant biotechnology, and clinical research. Our collective experience spans academia, industry, and translational science, driven by a shared mission to create scalable, accessible therapeutics that make a real-world difference.
We combine rigorous scientific thinking with a long-term view, partnering with leading research institutions and CROs to bring innovative biologics from concept to clinic. Our approach is collaborative by design, drawing on decades of experience across biology, drug development, regulatory planning, and platform engineering.
Meet the Team
Madis Metsis, PhD
Chief Scientific Officer & Co-Founder
Madis is a molecular neurobiologist with 40+ years of experience spanning neuroscience, genomics, immunology, and biotechnology. A former research lead at Karolinska Institute and author of over 120 peer-reviewed publications, his career has focused on gene expression, neurodegeneration, and translational innovation. At EdiLabs, he leads scientific direction, drawing on a lifelong belief that nature holds the answers to our most complex health challenges.
Kaisa brings 15 years of international experience in scaling startups and leading go-to-market strategy, partnerships, and operations across healthtech and sustainability. With a background at Eli Lilly, PwC UK, and The Clorox Company, she combines strategic insight with hands-on execution. At EdiLabs, she drives company vision, investor relations, and delivery to ensure bold ideas translate into real-world impact.
Kaisa Kangro
Chief Executive Officer & Co-founder
Sirje Rüütel Boudinot, PhD
Scientific Advisor, Immunology and Vaccine Design Advisor
Sirje is an expert in immunology and vaccine development, with extensive experience in molecular diagnostics and applied immunotherapy. She has contributed to EU-funded research across Estonia, Sweden, and France, and currently leads academic studies on immune activation and early diagnostics for Alzheimer’s disease at Tallinn University of Technology. At EdiLabs, Sirje supports immunological design and antigen development, drawing on her broad expertise across both research and translational science.
Toomas Toomsoo, PhD
Scientific Advisor, Neurology
Toomas is a leading neurologist with deep expertise in Alzheimer’s and Parkinson’s disease diagnostics and care. He currently serves as Head of the Internal Medicine Clinic and Consultant Neurologist at Confido Medical Centre and is Professor of Neurology at the University of Tallinn. With over three decades of clinical and academic leadership, including pioneering work in neuroimaging and early biomarker validation, he advises EdiLabs on neurodegenerative disease pathways, clinical translation, and long‑term patient impact.
Prof. Emeritus Bruno Conti, PhD
Scientific Advisor, Pharmacology, Ageing and Age-Associated Diseases
Prof. Conti is an internationally recognised biologist whose work spans pharmacology, neuroscience, and ageing. He is Professor at San Diego Biomedical Research Institute, Professor Emeritus at The Scripps Research Institute, and Adjunct Professor at Yale School of Medicine and Stockholm University. His pioneering work on neuroimmunology, temperature regulation, and neurodegeneration has advanced the understanding of ageing and inspired new approaches to complex age-related diseases.
Mariliis Eensalu, PhD
Global Business Strategy Advisor
Mariliis is a policy strategist with expertise at the intersection of science, diplomacy, and innovation. A published geochemist with training in international relations, she has led multilateral collaborations across government, academia, and industry. Her experience spans environmental policy, energy security, digital trust, and evidence-based negotiation. At EdiLabs, Mariliis advises on global business strategy, bringing technical expertise and diplomatic skill to advance sustainable, forward-looking biotech solutions.
Chris Bushe, PhD
Commercial Strategy & Industry Partnerships Advisor
Dr Chris Bushe is a pharmaceutical physician and researcher with over three decades of experience in clinical medicine, psychiatry, and pharmaceutical development. He has held senior medical leadership roles at Eli Lilly, Indivior, and Circassia, contributing to research, medical affairs, and patient engagement across psychiatry and neurology. Author of more than 70 scientific publications, book chapters, and conference papers, he brings together scientific insight, medical expertise, and commercial strategy.
PlantForm Corporation
Drug Development Partner
We have teamed up with PlantForm Corporation, a Canadian biopharmaceutical company with deep expertise in plant-based biologics. Known for its innovation in therapeutic protein development, PlantForm has supported global health and defence partners including DARPA, the Gates Foundation, and the NIH. At EdiLabs, PlantForm contributes trusted R&D capabilities and production insight as we advance our mission to deliver safe, accessible, and scalable therapies.
Charles River Laboratories
Preclinical Trials Partner
Charles River Laboratories is a world-leading contract research organisation (CRO) with deep expertise in preclinical neuroscience and Alzheimer’s disease. Our collaboration is centred at their Kuopio, Finland Discovery Research Services site: a hub of excellence in translational pharmacology focused on in vivo neuroscience models, advanced imaging, behavior, and biomarker analysis. As our preclinical trials partner, they support EdiLabs in validating safety, efficacy, and dosage using established AD models, guided by scientific and regulatory quality standards essential for therapeutic development.
Aera IP
Intellectual Property Strategy
Aera IP is a specialist intellectual property consultancy guiding biotech and deep tech startups through strategic IP planning, protection, and global patent filings. At EdiLabs, Aera supports the development of our IP portfolio from the earliest stages, helping secure our innovations through tailored, commercially-aligned strategies.